ANI Pharmaceuticals delivered its highest-ever quarterly revenue and its highest-ever adjusted EBITDA in the second quarter of 2026 - and, almost as importantly, it crossed a strategic threshold it had been working toward for two years. The company completed the build-out of a dedicated sales force targeting roughly 285,000 acute gouty arthritis patients treated by podiatrists and primary-care physicians, a population the existing rheumatology and nephrology sales organization could not reach. That sales force was fully operational as of the end of June. Within its first full quarter, every measurable leading indicator moved in the right direction: 95% of the new representatives generated multiple new patient cases, and more than a third of prescribers wrote two or more. Revenue of $266.0 million rose 25.9% year over year, driven by a 43.5% jump in Cortrophin Gel; adjusted EBITDA of $71.6 million rose 32.4%; and adjusted diluted earnings per share of $2.21 was 22.8% above the prior-year quarter. Operating cash flow for the first six months reached $115.0 million, and the company exited the quarter with $360.2 million of unrestricted cash and a freshly authorized $100 million share-repurchase program. The result is a small-cap specialty pharmaceutical whose single-product bet is no longer a question of whether, but of pace.
The quarter also carried a careful edit. Management lowered its full-year Cortrophin Gel revenue guide to $520 million–$540 million from the prior $540 million–$575 million, a roughly 4% trim at the midpoint, while reaffirming total-company guidance of $1,080 million–$1,140 million in net revenue and $285 million–$300 million in adjusted EBITDA. The path of the second-half guide is more demanding than the first half delivered: Cortrophin Gel must accelerate into the back half to hit the new range, and management said so plainly, framing the change as conservatism while the gout-expansion metrics mature. With the stock at $75.12 on August 12, having pulled back roughly a quarter from its 52-week high of $99.50 set in September 2025, ANI trades at roughly 8.7x trailing twelve-month adjusted earnings and 7.6x trailing twelve-month adjusted EBITDA - a low double-digit multiple of a business delivering mid-20s revenue growth and operating-cash-flow compounding. The next quarter, when the gout expansion's first real selling period under a full national footprint gets reported, is the test that decides whether the re-rating is already in or is still ahead.